The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
A Prospective, Randomized, Open-Label Trial of Early versus Late Favipiravir Therapy in Hospitalized Patients with COVID-19
Open accessAbstract
Favipiravir is an oral broad-spectrum inhibitor of viral RNA-dependent RNA polymerase that is approved for treatment of influenza in Japan. We conducted a prospective, randomized, open-label, multicenter trial of favipiravir for the treatment of COVID-19 at 25 hospitals across Japan. Eligible patients were adolescents and adults admitted with COVID-19 who were asymptomatic or mildly ill and had an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. Patients were randomly assigned at a 1:1 ratio to early or late favipiravir therapy (in the latter case, the same regimen starting on day 6 instead of day 1).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wu, Z., & McGoogan, J. M. (2020) · JAMA · doi:10.1001/jama.2020.2648 · Cited by 17,016
Cited by
Drug treatments for covid-19: living systematic review and network meta-analysis
Siemieniuk, R. A., Bartoszko, J. J., Zeraatkar, D., Kum, E., Qasim, A., Díaz Martinez, J. P., Izcovich, A., Rochwerg, B., Lamontagne, F., Han, M. A., et al. (2020) · BMJ · doi:10.1136/bmj.m2980 · Cited by 846
Role of favipiravir in the treatment of COVID-19
Joshi, S., Parkar, J., Ansari, A., Vora, A., Talwar, D., Tiwaskar, M., Patil, S., & Barkate, H. (2021) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2020.10.069 · Cited by 462
Udwadia, Z. F., Singh, P., Barkate, H., Patil, S., Rangwala, S., Pendse, A., Kadam, J., Wu, W., Caracta, C. F., & Tandon, M. (2021) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2020.11.142 · Cited by 282
Hassanipour, S., Arab-Zozani, M., Amani, B., Heidarzad, F., Fathalipour, M., & Martinez-de-Hoyo, R. (2021) · Scientific Reports · doi:10.1038/s41598-021-90551-6 · Cited by 264
Metadata
- Authors
- Doi, Y., Hibino, M., Hase, R., Yamamoto, M., Kasamatsu, Y., Hirose, M., Mutoh, Y., Homma, Y., Terada, M., Ogawa, T., Kashizaki, F., Yokoyama, T., Koba, H., Kasahara, H., Yokota, K., Kato, H., Yoshida, J., Kita, T., Kato, Y., Kamio, T., Kodama, N., Uchida, Y., Ikeda, N., Shinoda, M., Nakagawa, A., Nakatsumi, H., Horiguchi, T., Iwata, M., Matsuyama, A., Banno, S., Koseki, T., Teramachi, M., Miyata, M., Tajima, S., Maeki, T., Nakayama, E., Taniguchi, S., Lim, C. K., Saijo, M., Imai, T., Yoshida, H., Kabata, D., Shintani, A., Yuzawa, Y., & Kondo, M.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2020-11-17
- Volume
- 64
- Issue
- 12
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W3087465356
- Cited by
- 223
- References
- 1
- FWCI
- 5.79
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Prospective, Randomized, Open-Label Trial of Early versus Late Favipiravir Therapy in Hospitalized Patients with COVID-19. https://app.cochat.ai/papers/10.1128/aac.01897-20
- The paper
- Doi, Y., Hibino, M., Hase, R., Yamamoto, M., Kasamatsu, Y., Hirose, M., Mutoh, Y., Homma, Y., Terada, M., Ogawa, T., Kashizaki, F., Yokoyama, T., Koba, H., Kasahara, H., Yokota, K., Kato, H., Yoshida, J., Kita, T., Kato, Y., . . . Kondo, M. (2020). A Prospective, Randomized, Open-Label Trial of Early versus Late Favipiravir Therapy in Hospitalized Patients with COVID-19. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.01897-20
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.